^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TQB2934
i
Other names: TQB2934
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
CD3 agonist, BCMA inhibitor
Related drugs:
1d
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors (clinicaltrials.gov)
P1, N=42, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • IO biomarker
|
TQB2934
7d
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients (clinicaltrials.gov)
P1/2, N=70, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
New P1/2 trial
|
TQB2934
3ms
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors (clinicaltrials.gov)
P1, N=42, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial • IO biomarker
|
TQB2934
over2years
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects (clinicaltrials.gov)
P1, N=140, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • IO biomarker
|
IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
IL10 elevation
|
TQB2934
3years
A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects (clinicaltrials.gov)
P1, N=140, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • IO biomarker
|
IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
TQB2934
Share via
